Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 24: New Insights from CLEAR OUTCOMES
Author(s): Marc P Bonaca Added: 1 year ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
ESC 25: The NEWTON-CABG CardioLink-5 Study
Author(s): Subodh Verma Added: 7 months ago
ESC Congress 2025 - NEWTON-CABG finds evolocumab with regular statin therapy did not improve vein graft patency after coronary artery bypass graft (CABG) surgery in the short-term.Dr Subodh Verma and Dr Lawrence Leiter (University of Toronto, Toronto, CA) join us to discuss findings from NEWTON-CABG CardioLink-5 (NCT03900026). The investigator-initiated multicenter, randomised, placebo-controlled… View more

Intervention
Ez-PAVE: Lower LDL-C Target Reduces CV Events
Added: 6 days ago Source:  Radcliffe CVRM
Recent US guidelines have controversially recommended lowering the low-density lipoprotein cholesterol (LDL-C) target to <55 mg/dL for patients with established atherosclerotic cardiovascular disease (ASCVD).¹˒² The Ez-PAVE trial is the first randomised study to directly compare this intensive target with a conventional target of <70 mg/dL. The findings were published in The New England… View more

Cardiovascular Kidney Metabolic

Demographic
Job title: Clinical Professor and Director of Preventive Cardiology
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 1 year ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
HsCRP in ASCVD
HsCRP in ASCVD

Review Article

Author(s): Adhya Mehta , Roger S Blumenthal , Ty J Gluckman , et al Added: 1 year ago

Prevention & Chronic Conditions
Jane Armitage
Research Area(s) / Expertise: Job title: Professor of Clinical Trials and Epidemiology, and Honorary Consultant in Public Health Medicine
Jane Armitage, FRCP, FFPH, OBE, is Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine and also Director of Training and Career Development for the Nuffield Department of Population Health. She works on the epidemiology of cardiovascular disease and has led large-scale randomized controlled trials. Dr Armitage is Chief Investigator for the BHF-supported… View more
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 5 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

MI/ACS

Prevention & Chronic Conditions
Job title: Full Professor of Pharmacology